Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose alkylating chemotherapy for HRD oligometastatic breast cancer
NL-OMON36155Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide, carboplatin, thiotepa, docetaxel, doxorubicin and 3 more in breast cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Three-year progression-free survival. Planned start May 2011; status: withdrawn.
02
Drugs
cyclophosphamidecarboplatinthiotepadocetaxeldoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON36155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36155.